leadf
logo-loader
viewOrgenesis

Full interview: Orgenesis signs deal with Accellix, invites Academy Award winner on Scientific board

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process analytics. 

Kaplan also told Proactive about the newest member of their Scientific Board, Dr Bala Manian, and why she feels he is the right fit for the company.

Quick facts: Orgenesis

Price: 6.54 USD

NASDAQ:ORGS
Market: NASDAQ
Market Cap: $157.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

ArcPacific Resources Corp taking modern approach to historic properties in...

ArcPacific Resources (CVE: ACP) CEO Adrian Smith joined Steve Darling from Proactive to bring news from the company’s Lucky Mike Silver Lode Project near Merritt, BC. Smith shares with Proactive that after completing data compilation they have identified highly elevated gold, copper and silver...

47 minutes ago

2 min read